0001213900-23-033454.txt : 20230428 0001213900-23-033454.hdr.sgml : 20230428 20230428061005 ACCESSION NUMBER: 0001213900-23-033454 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230428 DATE AS OF CHANGE: 20230428 EFFECTIVENESS DATE: 20230428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allarity Therapeutics, Inc. CENTRAL INDEX KEY: 0001860657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-480262 FILM NUMBER: 23859901 BUSINESS ADDRESS: STREET 1: 24 SCHOOL ST., 2ND FLOOR CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 401-426-4664 MAIL ADDRESS: STREET 1: 24 SCHOOL ST., 2ND FLOOR CITY: BOSTON STATE: MA ZIP: 02108 D 1 primary_doc.xml X0708 D LIVE 0001860657 Allarity Therapeutics, Inc. 24 SCHOOL STREET, 2ND FLOOR BOSTON MA MASSACHUSETTS 02108 (401) 426-4664 DELAWARE None None Corporation true 2021 James G. Cullem 24 School Street, 2nd Floor Boston MA MASSACHUSETTS 02108 Executive Officer Director Joan Brown 24 School Street, 2nd Floor Boston MA MASSACHUSETTS 02108 Executive Officer Gerald McLaughlin 24 School Street, 2nd Floor Boston MA MASSACHUSETTS 02108 Director David A. Roth 24 School Street, 2nd Floor Boston MA MASSACHUSETTS 02108 Director Thomas Jensen 24 School Street, 2nd Floor Boston MA MASSACHUSETTS 02108 Executive Officer Director Steen Knudsen 24 School Street, 2nd Floor Boston MA MASSACHUSETTS 02108 Executive Officer Marie Foegh 24 School Street, 2nd Floor Boston MA MASSACHUSETTS 02108 Executive Officer Biotechnology Decline to Disclose 06b false 2023-04-21 false true true true Series A Preferred Stock issued in connection with a secured promissory note, and Common Stock issuable upon conversion of Series A Preferred Stock false 0 350000 350000 0 Represents the principal amount of $350,000 of a secured promissory note convertible into shares of Series A Convertible Preferred Stock false 1 0 0 0 false Allarity Therapeutics, Inc. /s/ James G. Cullem James G. Cullem Chief Executive Officer 2023-04-28